

To: AmeriHealth Caritas Louisiana Providers

Date: March 30, 2023

Subject: Improve Chronic Hepatitis C Virus (HCV) Pharmaceutical Treatment Initiation Rate

Summary: Information is provided regarding HCV Pharmaceutical Treatment

AmeriHealth Caritas Louisiana members have access to safe and effective treatment for Hepatitis C. In conjunction with treatment, AmeriHealth Caritas Louisiana is providing education to practitioners regarding evidence-based treatment and formulary coverage.

The most common risk factor for HCV is past or current injection drug use. Members with Human Immunodeficiency Virus (HIV) are also at higher risk to contract HCV due to shared transmission modes.⁽³⁾

As a reminder, there should still be *routine periodic testing* for people with ongoing risk factors *and* for any person who requests Hepatitis C testing. Click to view the CDC's <u>recommended</u> <u>testing sequence for identifying current hepatitis c virus infection</u> and also the <u>recommended</u> <u>interpretation of test results and further actions</u>.

What do you need to know? One of the approved pharmaceutical treatments is **Epclusa** (sofosbuvir/velpatasvir). Members have open access to the authorized generic (AG) of Epclusa, which has proven effective in curing 95% of persons living with HCV.⁽¹⁾ Generic Epclusa is the preferred direct-acting antiviral (DAA) which may be taken over the course of 12 weeks and *does not require prior authorization* unlike other available treatment regimens.⁽²⁾

More members may be treated due to the simplification of treatment regimen and the increased number of providers who can prescribe the medication, including primary care providers, specialists, nurse practitioners and physician assistants. For more information regarding Epclusa, please view the Epclusa prescribing information here.

References:

¹ Louisiana Department of Health (LDH). Hepatitis C. http://ldh.la.gov/index.cfm/page/1012 [4 November 2019a].

³ Louisiana Office of Public Health (LA OPH). Epidemiologic Profile of Hepatitis C Virus Infection in Louisiana – 2015.

² Louisiana Medicaid. Authorization Criteria for Hepatitis C DAA Agents for Medicaid July 2019.

Questions:

Thank you for your continued support and commitment to the care of our members. If you have questions about this communication, please contact AmeriHealth Caritas Louisiana's Provider Services department at 1-888-922-0007 or your <u>Provider Network Management</u> <u>Account Executive</u>.

Missed an alert?

You can always find a complete listing of provider alerts on the <u>Newsletters and Updates</u> page of our website.

Need to update your provider information? Send full details to <u>network@amerihealthcaritasla.com</u>

Where can I find more information on COVID-19?

AmeriHealth Caritas Louisiana has updated its website to streamline communications and important notifications about COVID-19. Please visit <u>http://amerihealthcaritasla.com/covid-19</u> for up-to-date information for both providers and members, including frequently asked questions, cancellations and postponements, and important provider alerts from AmeriHealth Caritas Louisiana and the Louisiana Department of Health.